Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes

The prevalence of pregnant individuals with opioid use disorder continues to increase posing health risks to women, fetuses, and children as well as challenges and costs to society [1]. Opioid maintenance treatment during pregnancy is beneficial and widely recommended but carries risks, hence knowledge of the safety profiles of pharmacotherapies is required [2]. Neonates exposed to buprenorphine may experience less severe neonatal opioid withdrawal syndrome than those exposed to methadone [3,4].
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Tags: Full length article Source Type: research